Company Registration No. 07179980 (England and Wales)
Vekade Pharma Limited
Unaudited accounts
for the year ended 31 March 2025
Vekade Pharma Limited
Unaudited accounts
Contents
Vekade Pharma Limited
Company Information
for the year ended 31 March 2025
Company Number
07179980 (England and Wales)
Registered Office
Unit 15, The Wenta Business Centre
Colne Way
Watford
Herts
WD24 7ND
United Kingdom
Accountants
Infinity Accountants
27 Coniston Gardens
Pinner
Middlesex
HA5 2JN
Vekade Pharma Limited
Statement of financial position
as at 31 March 2025
Tangible assets
40,400
16,000
Cash at bank and in hand
13,564
25,781
Creditors: amounts falling due within one year
(147,909)
(189,860)
Net current (liabilities)/assets
(13,412)
6,555
Total assets less current liabilities
26,988
22,555
Provisions for liabilities
Called up share capital
10
10
Profit and loss account
24,985
22,545
Shareholders' funds
24,995
22,555
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 11 December 2025 and were signed on its behalf by
Mr K Mandanka
Director
Company Registration No. 07179980
Vekade Pharma Limited
Notes to the Accounts
for the year ended 31 March 2025
Vekade Pharma Limited is a private company, limited by shares, registered in England and Wales, registration number 07179980. The registered office is Unit 15, The Wenta Business Centre, Colne Way, Watford, Herts, WD24 7ND, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
The accounts are presented in £ sterling.
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Motor vehicles
20% reducing balance
Fixtures & fittings
20% reducing balance
Inventories have been valued at the lower of cost and estimated selling price less costs to complete and sell. In respect of work in progress and finished goods, cost includes a relevant proportion of overheads according to the stage of manufacturing/completion.
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's accounts. Deferred tax is provided in full on timing differences which result in an obligation to pay more (or less) tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws.
Deferred tax assets and liabilities are not discounted.
Vekade Pharma Limited
Notes to the Accounts
for the year ended 31 March 2025
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
4
Tangible fixed assets
Motor vehicles
Fixtures & fittings
Total
Cost or valuation
At cost
At cost
At 1 April 2024
-
20,000
20,000
At 31 March 2025
34,500
20,000
54,500
At 1 April 2024
-
4,000
4,000
Charge for the year
6,900
3,200
10,100
At 31 March 2025
6,900
7,200
14,100
At 31 March 2025
27,600
12,800
40,400
At 31 March 2024
-
16,000
16,000
Amounts falling due within one year
Trade debtors
3,420
66,270
Accrued income and prepayments
75,584
60,000
6
Creditors: amounts falling due within one year
2025
2024
Trade creditors
104,961
120,857
Taxes and social security
4,248
9,353
Loans from directors
4,163
4,163
7
Average number of employees
During the year the average number of employees was 3 (2024: 3).